The Gold Standard Chassis for Industrial Protein and Chemical Production. Bacillus subtilis is a premier "workhorse" in the biotechnology sector, renowned for its extraordinary protein secretion capacity and FDA-recognized GRAS status. CD Biosynsis provides high-efficiency, scarless gene knockout and comprehensive genome engineering services for B. subtilis. Our platform is designed to transform this model organism into a high-performance cellular factory, ensuring your research moves seamlessly from the laboratory to industrial-scale production.
Get a Technical QuoteOur B. subtilis platform goes beyond simple gene inactivation. We focus on enhancing strain robustness and productivity through systematic genome streamlining and precise expression fine-tuning.
| Service Tier | Technical Strategy | Best For | Standard Deliverables |
|---|---|---|---|
| Standard Knockout | CRISPR-Cas9 / Recombination | Single gene disruption (e.g., protease removal) | 2 Validated stocks + Sanger Report |
| Pathway Engineering | Multi-gene Inactivation | Metabolic flux redirection (byproduct removal) | Optimized strain + Metabolic profile data |
| Genome Streamlining | Large-fragment Deletion | Creating a "Minimal Chassis" for stability | Streamlined strain + WGS |
| Advanced Expression | KIKO (Knock-in/Knock-out) | Chromosomal integration for markerless expression | Stable integrated strain + Expression QC |
1. Consultation & Design
2. Vector Construction
3. Transformation & Editing
4. Validation & Delivery
Target evaluation, codon optimization, and sgRNA/homology arm design.
Formal project proposal and Mutual NDA signing.
Assembly of CRISPR-Cas9 plasmids or scarless donor DNA templates.
Synthesis of custom regulatory elements.
Introduction via natural competence or electroporation protocols.
Multi-step screening and curing of temporary editing vectors.
Validation via Junction PCR and Sanger sequencing.
Final QC report delivery (Optional NGS/WGS).
To provide the highest level of service, our team continuously benchmarks our internal protocols against landmark studies in the field of Bacillus engineering.
Research has demonstrated that deleting approximately 20.7% (874 kb) of non-essential regions in the B. subtilis genome significantly improves cell yield and increases the specific productivity of recombinant enzymes. We apply this "Genome Streamlining" logic to help clients build more efficient and stable cellular machineries.
(Reference: Manabe et al., Applied and Environmental Microbiology)
In chiral chemical production, the deletion of bdhA (to abolish D-2,3-butanediol production) and acoA (to prevent precursor degradation), combined with pta and ldh knockouts, enables the high-purity production of meso-2,3-butanediol. We leverage these pathway redirection strategies for customized high-purity chemical synthesis.
(Reference: Fu et al., Biotechnology for Biofuels)
As a superior host for heterologous protein production, optimizing promoter strength and molecular chaperones is critical. We reference the latest advances in promoter engineering and protease management to provide comprehensive solutions for protein secretion optimization.
(Reference: Liu & Yu, Microbial Cell Factories)
1. Which knockout technology do you typically use?
We utilize either CRISPR-Cas9 systems or counter-selection systems depending on the project; both deliver precise, scarless edits.
2. Why choose B. subtilis over E. coli?
It has a single-layer cell wall for efficient secretion and is endotoxin-free, making it safer for clinical and food applications.
3. Can you perform large-fragment genome deletions?
Yes. We can delete large non-essential regions, such as prophages, ranging from dozens to hundreds of kilobases.
4. What if I need to knock-in a large metabolic pathway?
We offer KIKO services to stably integrate large pathways into the genome, providing higher stability than plasmid-based expression.
5. How do you verify the absence of off-target mutations?
Beyond standard Sanger sequencing, we recommend Whole Genome Sequencing (WGS) for complex or multi-locus projects.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.